21 results about "Abnormal glucose" patented technology

The invention discloses bifidobacterium adolescentis for relieving estrogen-related metabolic disorder and obesity and application thereof, and belongs to the technical field of microorganisms. The bifidobacterium adolescentis CCFM1506 screened by the invention can effectively improve ovariectomized individual estrogen disorder symptoms, obviously slow down the weight increase speed and weight increment of estrogen disorder individuals, increase the expression quantity of serum estradiol, CYP11A1 and ERalpha in adrenal gland and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose level and improve the ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized abnormal glucose and lipid metabolism is adjusted; the invention has the advantages of simple preparation method and wide application prospect, can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, and can be used for preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat, and has obvious physiological effects and wide application prospects, and can be used for preparing the medicines for relieving or treating the estrogen-related metabolic disorders and obesity and preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat. A new thought and a new basis are provided for developing functional foods or medicines based on the probiotics.

The invention provides an abnormal glycolipid metabolism risk dynamic assessment system based on SNP and gene analysis and application of the system in neuropsychiatric drug therapy, and belongs to the technical field of biological medicine. The system disclosed by the invention contains the primer probe group for detecting the metabolic influence of the antipsychotic drug, so that specific amplification detection of a specific SNP site can be realized, clinical guidance is targeted, and abnormal glucose and lipid metabolism and significant change of body weight are avoided. According to the method, glucose and lipid metabolism and effect target gene detection products are adopted for detection, a detection result is evaluated and interpreted through a glucose and lipid metabolism abnormal risk dynamic evaluation algorithm, retrospective investigation and actual case observation are combined, the detection result is good in sensitivity, high in accuracy and high in practicability, sampling is convenient, the evaluation algorithm is professional and reasonable, and the method is suitable for popularization and application. Results are easy to understand and easy to popularize and use.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to wheat bran araboxylan and application thereof. The invention provides wheat bran AX with specific molecular weight and monosaccharide composition. The wheat bran AX comprises the following monosaccharides: 0.20%-0.22% of glucuronic acid, 0.58%-0.62% of galacturonic acid, 0.21%-0.23% of rhamnose, 0.6%-0.7% of glucose, 1.4%-1.5% of galactose, 18%-19.2% of xylose and 21%-23% of arabinose. Compared with commercially available wheat bran AX, inulin, fructo-oligosaccharide and other common dietary fibers, the self-made wheat bran AX has higher diversity of microbial communities in the fermentation process, has a better intestinal flora regulating effect, further has a good relieving effect on the abnormal glucose and lipid metabolism of the body, and can be used for preventing and treating the abnormal glucose and lipid metabolism of the body. Therefore, the traditional Chinese medicine composition has a good regulation effect on various diseases such as non-alcoholic fatty liver and the like caused by abnormal glucose and lipid metabolism of the organism.

The invention provides emblic leafflower fruit polysaccharide with a weight losing effect and an efficient preparation method and application thereof, and belongs to the field of plant polysaccharide. The preparation method comprises the following steps: performing powdering, water extraction and concentration on a phyllanthus emblica raw material, adding an alcohol solvent for precipitation, and drying to obtain phyllanthus emblica crude polysaccharide; after the phyllanthus emblica crude polysaccharide is dissolved, impurities are removed through membrane filtration, protein substances are adsorbed through a reversed-phase chromatographic column, flow-through liquid and water leacheate are collected and combined, small-molecular-weight substances are removed through a membrane bag, intercepted liquid is collected and dried, and the phyllanthus emblica polysaccharide is obtained. The phyllanthus emblica polysaccharide has alpha-type and beta-type glycosidic bonds, and has linear polysaccharide chains and aggregates formed by a plurality of chains. The emblic leafflower fruit polysaccharide is used for preparing products for reducing fat and blood sugar, and can also be used for preparing medicines for preventing and treating abnormal glucose metabolism, abnormal lipid metabolism, related diseases, obesity and liver injury caused by obesity. The phyllanthus emblica polysaccharide extraction and purification preparation method is simple and efficient, and is convenient for industrial implementation.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The application provides a traditional Chinese medicine composition for preventing and treating metabolic-related fatty liver disease combined with type 2 diabetes and application thereof, and the traditional Chinese medicine composition is made of raw materials in the following weight parts: 6-30 parts of Huangqi, 0-20 parts of Ganjiang, 4-20 parts of Shaoyao, 4-20 parts of Gancao and 2-30 parts of Dazao. The medicine provided by the application can simultaneously significantly improve the abnormal glucose metabolism and liver metabolism damage of a "sugar-liver comorbidity" model animal, realizes integrated intervention on a core pathological link of the disease, can produce an unexpected integrated treatment effect on the "sugar-liver comorbidity", significantly reduces adverse reactions of diarrhea, improves gastrointestinal tolerance, is more suitable for the core pathogenesis of the "sugar-liver comorbidity" with cold and heat mixed together, and is beneficial to improving long-term medication safety.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

The invention discloses a method for screening diabetes treatment targets by using drosophila melanogaster as a model organism, and belongs to the technical field of biological medicines. According to the invention, a GAL4 / UAS system is utilized to construct transgenic drosophila melanogaster of which the specificity of a target gene (X) is knocked down, and F1-generation male ppl-GAL4 / + is obtained through hybridization; uAS-X RNAi / + drosophila melanogaster; compared with a high-glucose model control group with the same background, if the X gene knocks down, lipid droplet accumulation is reduced, and circulating glucose and trehalose are reduced (both have statistical significance, Plt, 0.05), the X gene is identified as a potential diabetes (abnormal glucose and lipid metabolism) treatment target. The method provided by the invention overcomes the problems of high cost, low efficiency, insufficient individuation and the like in the existing diabetes drug screening method, and provides an accurate, rapid, efficient and low-cost screening means for research and development of diabetes treatment drugs.

The invention belongs to the field of genetic engineering animal models, and particularly relates to a specific Foxp4 gene knockout mouse model and a construction method and application thereof. The method comprises the following steps: by utilizing a Cre-loxP system, obtaining Foxp4-fl / fl from a Foxp4-fl / fl from a Foxp4-fl / + heterozygote mouse and an Alb-Cre mouse through a mating strategy; and the liver-specific Foxp4 knockout mouse model is constructed by using the Foxp4 knockout mouse and an Albcre / + mouse. The invention finds for the first time that the Foxp4 plays an important role in maintaining the steady state function of the liver, the deficiency of the Foxp4 leads to phenotypes such as lipid accumulation in the liver, inflammatory cell infiltration, liver cell function damage, mild fibrosis and abnormal glucose and lipid metabolism, and the phenotypes are highly consistent with early symptoms and molecular characteristics of NAFLD; the Foxp4 gene has important application value in the aspects of researching the effect of the Foxp4 gene in the occurrence and development mechanism of the NAFLD and the maintenance of liver homeostasis, developing NAFLD-related therapeutic drugs and the like.

The application discloses a strain of Bifidobacterium adolescentis for relieving estrogen-related metabolic disorders and obesity and an application thereof, and belongs to the technical field of microorganisms. The Bifidobacterium adolescentis CCFM1506 screened by the application can effectively improve the symptoms of estrogen disorders of ovariectomized individuals, significantly slow down the weight growth rate and weight increment of individuals with estrogen disorders, increase the expression amounts of serum estradiol, CYP11A1 and ERa in adrenal glands and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose levels, adjust abnormal glucose and lipid metabolism, increase SCFA in colon contents, relieve menopausal syndrome caused by the decrease of estrogen, and can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, or health care products for helping to control fat in the body and maintain the healthy level of blood lipids. The significant physiological effect and wide application prospect provide a new thought and new basis for developing functional foods or medicines based on probiotics.

The invention discloses a medium-chain and long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood lipid, the composition comprises a grease component and a probiotic component, the grease component takes myristic acid as main fatty acid, MA accounts for 50-70% of the total amount of fatty acid in grease, and the grease component is compounded with medium-chain triglyceride and high-oleic-acid sunflower seed oil. And the probiotic component is bifidobacterium pseudocatenum, and the viable count of the bifidobacterium pseudocatenum is preferably 1 * 10 < 9 >-1 * 10 < 11 > CFU / g. Animal experiments verify that the composition can significantly reduce fasting blood-glucose, improve oral glucose tolerance damage and significantly reduce serum total cholesterol and triglyceride levels. Compared with single use of MA grease or single use of Bifidobacterium pseudocatenuicola, the composition provided by the invention shows a better comprehensive effect in the aspects of regulating blood sugar and blood fat, can be applied to functional foods, nutritional supplements and pharmaceutical preparations, and is used for preventing or assisting in improving abnormal glucose and lipid metabolism.

The invention relates to the field of microorganisms, in particular to application of Cristinia parvata in preparation of products for preventing and / or improving obesity and / or glucose and lipid metabolism disorder. The invention provides Christsenella minuta, and the preservation number of the Christsenella minuta is CGMCC (China General Microbiological Culture Collection Center) No.46901. The invention also provides a preparation method of the Christsenella minuta. The Cristsenella minuta provided by the invention can effectively inhibit the serum uric acid value of an organism, reduce the blood sugar level, improve reproductive injury caused by abnormal metabolism, effectively regulate and control abnormal glucose and lipid metabolism, and can improve symptoms such as obesity and / or hyperuricemia and / or gout diseases.

The present invention provides the use of SRSF1 in the preparation of drugs for preventing and / or treating heart failure with preserved ejection fraction, and belongs to the field of biomedicine technology. The present invention determines that SRSF1 can be used as a key target for the preparation of drugs related to the prevention and / or treatment of heart failure with preserved ejection fraction. By constructing animal models and cell-level experiments, it was confirmed that SRSF1 is involved in regulating the pathological process of the disease. The model experiments constructed in SRSF1 endothelial cell-specific knockout mice showed that inhibiting SRSF1 expression can improve symptoms such as diastolic dysfunction and hypertension, reduce pulmonary edema, and inhibit myocardial fibrosis and remodeling. It can also improve abnormal glucose and lipid metabolism and inhibit the process of endothelial-mesenchymal transition. The present invention opens up a new path for new drug screening, provides new targets and methods for the treatment of heart failure with preserved ejection fraction, and has important medical significance and value.

The invention discloses an early warning system and method for postpartum abnormal glucose metabolism of gestational diabetes mellitus, and relates to the technical field of diabetes mellitus monitoring, the system comprises a data acquisition module, a data processing and analysis module and an early warning module, the data acquisition module is used for acquiring data of postpartum abnormal and normal glucose metabolism patients; the data processing and analysis module is used for performing data processing and data analysis on the data, constructing a prediction model and training the model by using patient data; and the early warning module is used for performing risk assessment on the physiological data of the new patient to obtain a risk probability, performing risk grading and sending out early warning information. According to the system, physiological data are collected by integrating continuous blood glucose monitoring, a body fat scale, a sphygmomanometer and other equipment, diet records and life style tracking data of the smart bracelet are combined, comprehensive assessment of abnormal risk of glucose metabolism is achieved, key factors such as all-day blood glucose fluctuation, nutrition intake and sleep movement are covered, and the risk of abnormal risk of glucose metabolism is evaluated. And the timeliness and comprehensiveness of risk assessment are remarkably improved.

The invention discloses a medicine for treating hepatotoxicity of bosutinib by taking a CAMK2G gene or protein as a target spot, and belongs to the technical field of medicines. According to the medicine, the hepatotoxicity of bosutinib is relieved by down-regulating the expression of the CAMK2G gene or restoring the phosphorylation of the CAMK2G protein. The invention reveals that the CAMK2G gene is a key gene of liver injury and abnormal glucose metabolism caused by bosutinib, and provides a new prevention and treatment target for intervening hepatotoxicity caused by bosutinib. According to the invention, the CAMK2G phosphorylation activator is utilized to recover CAMK2G phosphorylation to relieve liver injury and abnormal glucose metabolism, a new direction is provided for finding an intervention strategy for causing hepatotoxicity by drugs, and the current situation that few intervention drugs can be used clinically and the mechanism is single is solved to a certain extent.

The invention relates to the technical field of biology, in particular to ADAD2 mutant protein with a hypoglycemic function and application, the ADAD2 mutant protein is obtained by mutating the 235th site of ADAD2 protein from Gly to Arg, and the amino acid sequence is shown as SEQ ID NO.2. In various hepatocytes, ADAD2 is over-expressed, the gluconeogenesis process is promoted, and the glucose production rate is increased; the glycosylation process of the over-expression ADAD2 G235R mutant is inhibited; after the expression of the wild ADAD2 is up-regulated, the fasting blood glucose level of a mouse is increased, the glucose tolerance is impaired, and meanwhile, the gluconeogenesis ability is enhanced; after the ADAD2 G213R mutant is up-regulated, the fasting blood glucose level of a mouse is reduced, the glucose tolerance is impaired and the gluconeogenesis ability is also reduced, and the ADAD2 gene missense mutant and the potential treatment effect thereof in regulating blood glucose and preventing and treating abnormal glucose metabolism can be used for preparing medicines for treating hyperglycemia and metabolic syndromes.

A use of INHBC as a target in the prevention and / or treatment of a metabolic disease. Provided is a use of a substance promoting the expression of an INHBC gene or improving the activity of an INHBC protein in the preparation of a product for preventing and / or treating a metabolic disease, wherein the metabolic disease comprises an energy metabolism dysfunction-induced disease, such as obesity, diabetes, fatty liver disease, or hyperlipidemia. Liver-specific overexpression or knock-in of INHBC can relieve liver steatosis and abnormal glucose metabolism in mice induced by a high-fat diet, and can also enhance the thermogenic activity of adipose tissues in the mice, thereby inhibiting obesity induced by the high-fat diet, showing significant application value in the prevention and / or treatment of metabolic diseases such as obesity, type 2 diabetes, and fatty liver diseases.

The application discloses application of 3-demethylcolchicine in medicine, and experiment proves that the 3-demethylcolchicine can obviously reduce the body weight and liver weight of NAFLD mice, can obviously reduce the liver injury and liver lipid deposition of the NAFLD mice, and can improve the liver function and abnormal glucose metabolism of the NAFLD, and has a wide application prospect in NAFLD medicine.

This invention discloses a traditional Chinese medicine composition and its application for treating various symptoms caused by spleen deficiency and stomach heat, with warming the spleen yang as the core of the formula. This invention reveals for the first time that modern people, due to excessive intake of animal-based foods, experience excessive stomach heat and a preference for cold foods, repeatedly damaging the spleen yang and forming a pathogenesis of "spleen deficiency and stomach heat," leading to various symptoms such as thirst, dry phlegm, dry and congested nose, obesity or emaciation, and abnormal glucose metabolism. Currently, Western medicine has no radical cure, and traditional Chinese medicine adheres to the theory of diabetes, resulting in poor efficacy. This invention innovatively uses warming the spleen yang as the core of the formula, creating a new formula based on the Da Bu Pi Tang (Great Spleen-Tonifying Decoction) in the *Fu Xing Jue* (Auxiliary Formula). It consists of herbs such as Codonopsis pilosula, prepared licorice root, dried ginger, Ophiopogon japonicus, Schisandra chinensis, Curcuma zedoaria, and Inula japonica. The formula has a rigorous combination of principal, assistant, and adjuvant herbs, warming the spleen without promoting heat and clearing away dampness without harming yang, precisely targeting the pathogenesis of spleen deficiency and stomach heat in modern people. This invention can be formulated into various oral dosage forms, with a simple formula, strong targeting, and high clinical value.

The invention discloses a compound dietary fiber low-GI steamed stuffed bun and a preparation method thereof, and belongs to the technical field of functional foods.Whole wheat flour is used as a main raw material, a dietary fiber composition formed by compounding soluble dietary fibers and insoluble dietary fibers according to a specific proportion is matched, a mulberry leaf extract and compound lactic acid bacteria powder are added in a synergistic mode, and the low-GI steamed stuffed bun is prepared. And step-type fermentation and steaming processes are combined, so that the steamed bun is prepared. Wherein the soluble dietary fiber is selected from resistant dextrin, fructo-oligosaccharide or inulin, and the insoluble dietary fiber is selected from oat fiber, wheat bran or pea fiber. Through collaborative optimization of dietary fiber types and proportions, functional ingredients and fermentation process conditions, the obtained steamed stuffed bun keeps good formability, tissue structure and processing adaptability, and meanwhile, the starch digestion rate is effectively reduced, so that a low glycemic index and a low blood sugar load are realized; the product disclosed by the invention is suitable for people with abnormal glucose metabolism and people with healthy diet requirements to eat, and has a good industrial application prospect.